Scopolamine
Brand names: Scopolamine, Transderm-Scop
At a glance
- Medicare prescriptions, 2024
- 124,449
- Medicare drug cost
- $10.8M
- Average cost per prescription
- $86.91
- Clinicians who prescribed it
- 5,607
Where it is prescribed
List the prescribers in any state, county, city or ZIP code →
What it is used for
Scopolamine transdermal system is indicated in adults for the prevention of: nausea and vomiting associated with motion sickness. post-operative nausea and vomiting (PONV) associated with recovery from anesthesia and/or opiate analgesia and surgery.
From the FDA-approved prescribing information (label dated September 2026). Full labels on DailyMed (opens in a new tab)
Who prescribes it
- Internal Medicine 32.2%
- Family Medicine 25.5%
- Nurse Practitioners 16.3%
- Physician Assistants 4.4%
- Geriatric Medicine 3.5%
- Neurology 1.9%
- Plastic Surgery 1.7%
- Hospitalist 1.7%
- General Practice 1.4%
- Gastroenterology 1.4%
- General Surgery 1.2%
- Pulmonology 1.2%
All prescribers, by place, name or specialty →
Share of Medicare prescriptions written by each specialty. Select one to list its prescribers.
Trend, 2019–2024
Medicare prescriptions rose 72% from 2019 to 2024.
Biggest change by state since 2019
- Florida +97%
- Ohio +93%
- Georgia +89%
- Texas +84%
- Indiana +83%
- Massachusetts (smallest change) +31%
- New Jersey (smallest change) +37%
From CMS’s yearly state and national Part D summaries, which count every prescriber, including those CMS leaves out of its per-clinician data (fewer than 11 prescriptions). That is why these totals are higher than the count at the top of this page. Prescriptions include refills.
What it looks like
Pills from 1 maker on file. The same medicine can look different depending on who made it, so check the imprint (the letters and numbers on the pill) with your pharmacist if a refill looks different.
Atlantic Biologicals Corp.
| Strength | Looks like | Imprint |
|---|---|---|
| 16.2 mg / 0.1037 mg hyoscyamine sulfate / 0.0194 mg atropine sulfate / 0.0065 mg scopolamine hydrobromide | purple elixir | |
Source: DailyMed (U.S. National Library of Medicine), from each maker’s FDA drug listing. A few makers are shown, not every one. Never take a pill you can’t identify; ask a pharmacist.
Industry payments about this drug
No industry payments to clinicians named this drug in 2025.
Recalls and shortages
Not on the FDA drug shortage list.
1 recall since 2020
- Apr 2022 · McKesson Medical-Surgical Inc. Corporate Office · Class II
cGMP deviations: Temperature abuse
Recalls usually affect specific lots from one maker, not every version of a drug. Class I is the most serious; most drug recalls are Class II. FDA recalls (opens in a new tab)
Sources: CMS Medicare Part D Prescribers by Provider and Drug (2024; prescriptions include refills, and CMS hides counts under 11 per prescriber); U.S. Food and Drug Administration, openFDA (drug labels, NDC directory, enforcement reports, drug shortages); CMS Open Payments 2025; ClinicalTrials.gov. General information only, not medical advice; not yet reviewed by our medical reviewer.